Physician profile
Lawrence Ross
NPI 1013956796
$481.16
in general payments reported to CMS, 2019-2025
11 companies · $55.64 in 2025
The $55.64 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.44 · 2020: $34.10 · 2021: $127 · 2022: $61.68 · 2023: $151 · 2024: $13.98 · 2025: $55.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $166.64 | 2021-2023 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.14 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $56.45 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $53.08 | 2022-2025 | Lotemax Sm, Prolensa, Zylet |
| Allergan, INC. | $32.24 | 2020-2021 | |
| Astellas Pharma US INC | $24.55 | 2025 | Izervay |
| Lilly USA, LLC | $20.17 | 2023 | Jardiance |
| Tarsus Pharmaceuticals, INC. | $15.82 | 2025 | Xdemvy |
| Alcon Vision LLC | $15.36 | 2022 | |
| Amgen INC. | $13.98 | 2024 | Tepezza |
| Shire North American Group INC | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.